How a Peninsula biotech turned its psoriasis drugs into a $2.4 billion acquisition
Small-molecule drugs supposedly are on the outs, but Lilly was willing to up its bid to nab two drugs targeting psoriasis.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news